Metrics to compare | LASA | Peers Peers - average of corresponding metrics from companies closely matching LASA: DISHTV, SECURKLOUD, UNITECH, 540694, RAJMET | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLASAPeersSector |
|---|---|---|---|---|
P/E Ratio | −1.3x | 7.2x | −0.2x | |
PEG Ratio | −0.03 | 0.07 | 0.00 | |
Price/Book | 0.4x | 0.7x | 2.6x | |
Price / LTM Sales | 3.4x | 0.6x | 2.8x | |
Upside (Analyst Target) | - | 48.5% | 60.9% | |
Fair Value Upside | Unlock | 2.4% | 9.5% | Unlock |
Lasa Supergenerics Limited engages in the manufacturing API bulk drugs products in India and internationally. It offers API products, such as fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, 2,6-diiodo-4-nitrophenol, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide; and Other API products. The company also provides animal feed ingredients; and reagents for therapeutic use. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.